Olgram is a biotechnology company fighting against antibiotic resistance by developing two programs:

1) An immunostimulatory drug after finding a new molecule in algae
2) New anti-infectives agents to kill resistant and persistent bacteria


Exploring the marine environment in order to find unique solutions for novel        anti-infectives

As bacteria become resistant to conventional antibiotics, we observe the emergence or re-emergence of infectious diseases. In addition, a lot of medical procedures such as chemotherapy and surgery become increasingly risky medical acts.

  • 700 000 people worldwide die from antibiotic-resistant infections and could rise to 10 million people by 2050 according to the WHO.
  • 671 000 infections and 33 000 people die in Europe due to antibiotic resistant antibiotics.
  • Antibiotic resistance Costs 1.5billion per year in the EU in healthcare and productivity losses


Products inspired from the oceans remain largely untapped sources for the discovery of new anti-infectives and immunostimulatory molecules thanks to its diverse and competitive environmental factors. They harbor diverse, uncharacterized and potential new sources of compounds. Exploring these new natural resources led us to the discovery of 2 new promising molecules to fight antibiotic resistance with key unique biological properties

Olgram algues

Our history

December 2019: Foundation of Olgram

Creation of Olgram, Spin off of the Olmix group.

June 2019: the project is awarded with grand laureate I-Lab price of the BPIFrance

The project MAPOLI (Marine Polysaccharides for Immunity) is granted grand Lauréat for the 2019 edition of the i-Lab competition


2017-2019 :preclinical collaborations with research institutes led to the discovery of the molecules involved in the immunostimulation

Biochemical research in USA and Europe led to the discovery of the molecules involved in the modulation of the immune system called the Marine Sulfated Polysaccharides (MSP)

Research between Olmix group and University of Nantes and Rennes 1 are engaged to study the effect of MSP and other molecules on the immune system and pathogens in relevant clinical models. Preclinical studies show very promising results on immunodepressed and infected models and patents are filled.

2016 Discovery of a new molecule by the Olmix Group in Algae

The Olmix group and the French National Public Institute for Agronomic Research (INRAe) have collaborated to demonstrate the effect of algae on the modulation of immune mediators in cellular models and in animals, including the identification of the metabolic pathways involved in this activation (Berri et al. 2016 and 2017).